A genetic variant carried by about 1 in 20 chemotherapy patients can turn a standard drug dose into a dangerous one. University of Michigan researcher Daniel Hertz discusses the research behind expanded genetic testing and why it matters for patients.
Expert Q&A: How U-M Research Helped Inform New FDA Warning to Protect Cancer Patients
June 23, 2026
•
Read time: 5-15 mins
Share: